7,11-Dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-10-prop-2-enyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 英文名称: 7,11-Dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-10-prop-2-enyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
• 化学式: C₃₀H₄₁NO₆S
• 分子量: 543.7
• InChiKey: BFZKMNSQCNVFGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  38
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Use of epothilones in the treatment of brain diseases associated with proliferative processes
  申请人：Schering Aktiengesellschaft

  公开号：EP1340498A1

  公开（公告）日：2003-09-03

  This invention provides the use of an Epothilone, which shows an average distribution coefficient between plasma and brain of 0.3 to 1.5 in the mouse intravenous bolus injection assay, for the preparation of a medicament for the treatment of a brain disease associated with proliferative processes.

  在小鼠静脉注射试验中，埃博霉素在血浆和大脑之间的平均分布系数为 0.3 至 1.5，本发明将这种埃博霉素用于制备治疗与增殖过程有关的脑部疾病的药物。
• Use of epothilones in the treatment of bone metastases and bone tumors or cancers
  申请人：Schering Aktiengesellschaft

  公开号：EP1640004A1

  公开（公告）日：2006-03-29

  The present invention relates to the use of Epothilones in the treatment of bone metastases and bone tumors or cancers, more particularly in treating, preventing or alleviating bone metastasis in a cancer patient.

  本发明涉及埃博霉素在骨转移和骨肿瘤或癌症治疗中的应用，尤其是在治疗、预防或减轻癌症患者骨转移方面的应用。
• Use of epothilones in the treatment of osteoporosis and related diseases
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1930004A1

  公开（公告）日：2008-06-11

  The present invention relates to the use of natural or synthetic Epothilones for the treatment or prophylaxis of diseases caused by a dysbalance of osteoclast and osteoblast activity, especially osteoporosis.

  本发明涉及天然或合成埃博霉素用于治疗或预防因破骨细胞和成骨细胞活性失衡引起的疾病，尤其是骨质疏松症。
• Use of Epothilones in the treatment of brain diseases associated with proliferative processes
  申请人：Schering AG

  公开号：US20040019088A1

  公开（公告）日：2004-01-29

  This invention provides the use of an Epothilone, which shows an average distribution coefficient between plasma and brain of 0.3 to 1.5 in the mouse intravenous bolus injection assay, for the preparation of a medicament for the treatment of a brain disease associated with proliferative processes.

  在小鼠静脉注射试验中，埃博霉素在血浆和大脑之间的平均分布系数为 0.3 至 1.5，本发明将这种埃博霉素用于制备治疗与增殖过程有关的脑部疾病的药物。
• USE OF EPOTHILONES IN THE TREATMENT OF BRAIN DISEASES ASSOCIATED WITH PROLIFERATIVE PROCESSES
  申请人：Schering AG

  公开号：EP1480643A1

  公开（公告）日：2004-12-01